Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07VYP
|
|||
| Drug Name |
Olutasidenib
|
|||
| Synonyms |
FT-2102; NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1
Click to Show/Hide
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Approved | [1] | |
| Glioma [ICD-11: 2A00.0] | Phase 1/2 | [2] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [3] | ||
| Company |
Rigel/Forma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H15ClN4O2
|
|||
| Canonical SMILES |
CC(C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N
|
|||
| InChI |
1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1
|
|||
| InChIKey |
NEQYWYXGTJDAKR-JTQLQIEISA-N
|
|||
| CAS Number |
CAS 1887014-12-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxalosuccinate decarboxylase (IDH1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Citrate cycle (TCA cycle) | |||
| Glutathione metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Carbon metabolism | ||||
| 2-Oxocarboxylic acid metabolism | ||||
| Biosynthesis of amino acids | ||||
| Peroxisome | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathwhiz Pathway | Warburg Effect | |||
| WikiPathways | TCA Cycle and PDHc | |||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in leukocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Peroxisomal lipid metabolism | ||||
| Glutathione metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215814. | |||
| REF 2 | ClinicalTrials.gov (NCT03684811) A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.